Figure 3.
Survival stratified by radiographic response is illustrated in (A) cohort 1 (standard chemoradiation [ChemoRT]), (B) cohort 2 (metastatic pancreatic ductal adenocarcinoma [PDAC]), (C) cohort 3 (protocol‐based gemcitabine plus chemoRT [GemRT]), and (D) cohort 4 (registry trial).